Adamis announces publication of comparative pharmacokinetics for naloxone
Adamis Pharmaceuticals Corporation announced that an article entitled "Comparative Pharmacokinetic Analysis of Community Use Naloxone Formulations for Acute Treatment of Opioid Overdose" was accepted for publication in the peer reviewed Journal of Addiction Research and Adolescent Behavior. The article compares the pharmacokinetics of two community naloxone formulations to Adamis' investigational drug ZIMHI in healthy subjects. Overall, the systemic levels of naloxone associated with the 2mg IM and 4mg IN were similar. By comparison, the naloxone levels associated with ZIMHI are higher with more rapid absorption. The authors concluded that "These results support the notion that higher doses of naloxone result in greater bioavailability, which may be required for reversal due to the more potent synthetic opioids such as fentanyl." Naloxone is an opioid antagonist used to treat narcotic overdoses. Naloxone works by reversing the detrimental effects of the opioid, including slowed breathing, brain dysfunction, loss of consciousness and death. Common opioids include morphine, heroin, tramadol, oxycodone, hydrocodone and fentanyl.